Rosetta Genomics Receives Accreditation from College of American Pathologists for its Laboratory in California
August 06 2015 - 8:00AM
Business Wire
Reflects high-quality standards of the
laboratory
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics,
announces that the Accreditation Committee of the College of
American Pathologists (CAP) has approved re-accreditation to
Rosetta Genomics’, Lake Forest, CA laboratory based on results of a
recent on-site inspection as part of the CAP’s Accreditation
Programs.
The facility’s laboratory director, Alfred Lui, MD, was notified
of this national recognition and congratulated for the excellence
of the services being provided. Rosetta Genomics’ Lake Forest
laboratory, along with its laboratory in Philadelphia, PA, are
among the more than 7,700 CAP-accredited facilities worldwide.
“Ongoing accreditation from CAP indicates compliance with the
most demanding good laboratory procedures and indicates that the
laboratory meets or exceeds regulatory requirements,” stated Dr.
Lui. “Receiving CAP Accreditation reaffirms our commitment to
providing the highest standard of cutting edge diagnostic
techniques.”
Commenting on the laboratory’s continued accreditation, Kenneth
A. Berlin, Rosetta Genomics’ President and Chief Executive Officer,
said, “The quality of our laboratory and testing services has
always been a core competency for Rosetta Genomics. We remain
committed to the development and performance of high-value as well
as high-quality molecular diagnostic testing services that advance
personalized medicine.”
The U.S. federal government recognizes the CAP Laboratory
Accreditation Program, begun in the early 1960s, as being equal-to
or more-stringent-than the government’s own inspection program.
During the CAP accreditation process, designed to ensure the
highest standard of care for all laboratory patients, inspectors
examine the laboratory’s records and quality control of procedures
for the preceding two years. CAP inspectors also examine laboratory
staff qualifications, equipment, facilities, safety program and
record, and overall management.
About the College of American Pathologists
As the leading organization with more than 18,000
board-certified pathologists, the College of American Pathologists
(CAP) serves patients, pathologists, and the public by fostering
and advocating excellence in the practice of pathology and
laboratory medicine worldwide. The CAP’s Laboratory Improvement
Programs, initiated 65 years ago, currently have customers in more
than 100 countries, accrediting 7,700 laboratories and providing
proficiency testing to 20,000 laboratories worldwide. Find more
information about the CAP at cap.org. Follow CAP on Twitter:
@pathologists.
About Rosetta Genomics
Rosetta develops and commercializes a broad range of
microRNA-based and other high-value molecular diagnostics.
Rosetta’s integrative research platform combining bioinformatics
and state-of-the-art laboratory processes has led to the discovery
of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company also offers core FISH, IHC and
PCR-based testing capabilities and partnerships in oncology and
urology that provide additional content and platforms that
complement the Rosetta offerings. Rosetta’s cancer testing services
are commercially available through the Philadelphia, PA- and Lake
Forest, CA-based CAP-accredited, CLIA-certified labs, respectively.
For more information visit www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects including, but not limited
to statements relating to Rosetta Genomics advancing
personalized medicine, constitute forward-looking statements for
the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, including those risks
more fully discussed in the "Risk Factors" section of Rosetta’s
Annual Report on Form 20-F for the year ended December 31,
2014 as filed with the SEC. In addition, any forward-looking
statements represent Rosetta’s views only as of the date of this
release and should not be relied upon as representing its views as
of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150806005207/en/
Rosetta GenomicsKen Berlin, 609-419-9003President &
CEOinvestors@rosettagenomics.comorInvestors:LHAAnne Marie Fields,
212-838-3777afields@lhai.comorBruce Voss,
310-691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Sep 2023 to Sep 2024